Table 2.

m6A inhibitors have different targets and mechanisms

Cancer/Disease	Drug	Target	Role	Mechanism
AML	STM2457	METTL3	Inhibitor	Weaken the proliferation of AML stem cells or leukemia
	SPI1	METTL14	Regulator	Promote terminal myeloid differentiation of normal HSPCs/AML Inhibit AML cell survival
	CS1/CS2	FTO	Inhibitor	Increase the sensitivity of AML cells to T cell toxicity
	R-2HG	FTO	Inhibitor	Inhibit the proliferation of AML and weaken aerobic glycolysis in sensitive leukemic cells
	FB23-2	FTO	Inhibitor	Suppress proliferation and promote the differentiation of AML
	Rhein	FTO	Inhibitor	Overcome tyrosine kinase inhibitor resistance
GBM	MA/MA2	FTO	Inhibitor	Suppress the growth and self-renewal of GSCs
Melanoma	ALK-04	ALKBH5	Inhibitor	Regulate the express of Mct4/Scl16a3 and lactic acid
BC	MO-I-500	FTO	Inhibitor	Suppress survival of BC cells by decreasing IRX3 proteins
LUAD	PKE Sorafenib	YTHDC2	Regulator	Suppress SLC7A11-dependent antioxidant function
Testicular damage	MEHP	FTO	Inhibitor	Regulate reduction of testosterone and increase of apoptosis